FLUCONAZOLE CYCLOSPORINE INTERACTION - A DOSE-DEPENDENT EFFECT

被引:53
作者
LOPEZGIL, JA
机构
[1] Resident in Clinical Pharmacology, Clinical Pharmacology Service, Hospital Universitario “Marqués de Valdecilla”, 39008, Santander
关键词
D O I
10.1177/106002809302700405
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To present cases supporting the hypothesis that fluconazole inhibition of cyclosporine metabolism is dose-dependent. DESIGN: Case reports. PATIENTS AND INTERVENTIONS: One renal-pancreatic transplant patient taking fluconazole 100 and 300 mg/d for 37 and 17 days, respectively; four bone marrow transplant recipients taking fluconazole 100 mg/d as antifungal prophylaxis and five other concurrent nonmatched recipients whose antifungal prophylactic agent is nystatin mouthwash. All of these patients underwent transplantation during the same period. RESULTS: There was a sharp rise in cyclosporine trough concentration (ng/mL), concentration:dose ratio (ng.mL-1/mg.kg-1), and serum creatinine concentration (mumol/L) in the renal-pancreatic transplantation patient taking fluconazole 300 mg/d. No such increase occurred at 100 mg/d. No significant alterations in cyclosporine concentration:dose ratio were seen in the patients undergoing bone marrow transplantation and receiving fluconazole 100 mg/d. CONCLUSIONS: The case of the renal-pancreatic transplantation patient shows a characteristic interaction profile, and it supports the hypothesis of a dose-dependent interaction between cyclosporine and fluconazole. Given the nephrotoxic potential of the immunosuppressant drug, dosage reduction and closer monitoring of cyclosporine concentrations and/or renal function in patients receiving fluconazole dosages greater than 200 mg/d must be considered.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 21 条
  • [1] CANAFAX DM, 1991, TRANSPLANT P, V23, P1041
  • [2] INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL-ALLOGRAFT RECIPIENTS
    CANAFAX, DM
    GRAVES, NM
    HILLIGOSS, DM
    CARLETON, BC
    GARDNER, MJ
    MATAS, AJ
    [J]. TRANSPLANTATION, 1991, 51 (05) : 1014 - 1018
  • [3] CONTI DJ, 1989, TRANSPLANTATION, V48, P692
  • [4] EHNINGER G, 1989, LANCET, V2, P104
  • [5] HEART-TRANSPLANTATION IN MILDLY DIABETIC-PATIENTS
    FAGLIA, E
    FAVALES, F
    MAZZOLA, E
    PIZZI, G
    DEMARIA, R
    MANGIAVACCHI, M
    GRONDA, E
    CAROLI, A
    ZAINA, MS
    [J]. DIABETES, 1990, 39 (06) : 740 - 742
  • [6] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    GOODMAN, JL
    WINSTON, DJ
    GREENFIELD, RA
    CHANDRASEKAR, PH
    FOX, B
    KAIZER, H
    SHADDUCK, RK
    SHEA, TC
    STIFF, P
    FRIEDMAN, DJ
    POWDERLY, WG
    SILBER, JL
    HOROWITZ, H
    LICHTIN, A
    WOLFF, SN
    MANGAN, KF
    SILVER, SM
    WEISDORF, D
    HO, WG
    GILBERT, G
    BUELL, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) : 845 - 851
  • [7] CYCLOSPORIN-ERYTHROMYCIN INTERACTION IN RENAL-TRANSPLANT PATIENTS
    GUPTA, SK
    BAKRAN, A
    JOHNSON, RWG
    ROWLAND, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) : 475 - 481
  • [8] KAHAN BD, 1990, TRANSPLANT P, V22, P1274
  • [9] DEMOGRAPHIC-FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY
    KAHAN, BD
    KRAMER, WG
    WIDEMAN, C
    FLECHNER, SM
    LORBER, MI
    VANBUREN, CT
    [J]. TRANSPLANTATION, 1986, 41 (04) : 459 - 464
  • [10] KRUGER HU, 1988, BONE MARROW TRANSPL, V3, P271